Clinical trial

Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors

NCT02592083

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Palbociclib Normalized identity: palbociclibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2015-10-01

PhasePHASE2

Conditions

Early-Stage Breast Carcinomaunresolved

Hormone Receptor Positive Tumorunresolved

Interventions

Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelinDRUG

PalbociclibDRUG · verified · RxNorm: palbociclib

Sponsors & collaborators

Thomas Hatscheklead sponsor

Mapped research locations

StockholmSweden1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02592083 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.